Q2 2024

Filed Aug 14, 2024 · 10-Q · 45 days after period end · 0001493152-24-032143

Q2 2024 · 10-Q

Revenue—

Net Income

-$3.71M

N/M vs Q2 2023

EPS Diluted

-$2.17

N/M vs Q2 2023

Operating Income-$3,906,000N/M

Operating Cash Flowderived-$3,536,000N/M

Same quarter

Metric	Q2 2024	Q2 2023	Q2 2022	Q2 2021
Revenue	—	—	—	$0.00
Net Income	-$3.71M	-$1.99M	-$2.98M	-$4.86M
EPS Diluted	-$2.17	-$1.49	-$0.10	-$0.15

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

GT Biopharma, Inc. · CIK 109657 · Engraved from SEC EDGAR